Rapid assessment of changes in phage bioactivity using dynamic light scattering

Extensive efforts are underway to develop bacteriophages as therapies against antibiotic-resistant bacteria. However, these efforts are confounded by the instability of phage preparations and a lack of suitable tools to assess active phage concentrations over time. In this study, we use dynamic ligh...

Full description

Saved in:
Bibliographic Details
Published inPNAS nexus Vol. 2; no. 12; p. pgad406
Main Authors Dharmaraj, Tejas, Kratochvil, Michael J, Pourtois, Julie D, Chen, Qingquan, Hajfathalian, Maryam, Hargil, Aviv, Lin, Yung-Hao, Evans, Zoe, Oromí-Bosch, Agnès, Berry, Joel D, McBride, Robert, Haddock, Naomi L, Holman, Derek R, van Belleghem, Jonas D, Chang, Tony H, Barr, Jeremy J, Lavigne, Rob, Heilshorn, Sarah C, Blankenberg, Francis G, Bollyky, Paul L
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Extensive efforts are underway to develop bacteriophages as therapies against antibiotic-resistant bacteria. However, these efforts are confounded by the instability of phage preparations and a lack of suitable tools to assess active phage concentrations over time. In this study, we use dynamic light scattering (DLS) to measure changes in phage physical state in response to environmental factors and time, finding that phages tend to decay and form aggregates and that the degree of aggregation can be used to predict phage bioactivity. We then use DLS to optimize phage storage conditions for phages from human clinical trials, predict bioactivity in 50-y-old archival stocks, and evaluate phage samples for use in a phage therapy/wound infection model. We also provide a web application (Phage-Estimator of Lytic Function) to facilitate DLS studies of phages. We conclude that DLS provides a rapid, convenient, and nondestructive tool for quality control of phage preparations in academic and commercial settings.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interest: A.O.-B., J.D.v.B., and R.M. are members of Felix Biotechnology, Inc., a phage therapy company. All other authors declare they have no competing interests.
ISSN:2752-6542
2752-6542
DOI:10.1093/pnasnexus/pgad406